Our data showed that gefitinib-treated TNBC cells exhibited enhanced production of proinflammatory cytokines/chemokines such as IL-6, IL-8, and CXCL2, hence increasing the number of tumor-infiltrating immune cells including IL-26-producing cells in the TME. This evidence concerns the gene CXCL2 and neoplasm.